Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
  1. Home
  2. Publications
  3. Supplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer

Supplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer

Authors:
  • CXCong Xing
    Cong Xing
  • XTXintao Tu
    Xintao Tu
  • WHWanwan Huai
    Wanwan Huai
  • ZTZhen Tang
    Zhen Tang
  • KSKun Song
    Kun Song
  • DJDevon Jeltema
    Devon Jeltema
  • KKKennady Knox
    Kennady Knox
  • NDNicole Dobbs
    Nicole Dobbs
  • KYKun Yang
    Kun Yang
  • NYNan Yan
    Nan Yan

Open Access
Publisher website
Google Scholar
  • 1 August 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/0008-5472.29759869
Abstract
Validation of Trex1-KO and double KO MC38 cells
Keywords
  • DRUG TARGETS
  • IMMUNOLOGY
  • INNATE IMMUNITY
  • TUMOR IMMUNOLOGY ANIMAL MODELS
  • IMMUNOTHERAPY
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.